Cargando…
Managing vitamin D deficiency in inflammatory bowel disease
Management of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is generally cumbersome for patients and is a massive health-economic burden. In recent years, the immunomodulating effects of vitamin D have gained a huge interest in its possible pathogenic influence...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788352/ https://www.ncbi.nlm.nih.gov/pubmed/31656565 http://dx.doi.org/10.1136/flgastro-2018-101055 |
_version_ | 1783458469251121152 |
---|---|
author | Nielsen, Ole Haagen Hansen, Thomas Irgens Gubatan, John Mark Jensen, Kim Bak Rejnmark, Lars |
author_facet | Nielsen, Ole Haagen Hansen, Thomas Irgens Gubatan, John Mark Jensen, Kim Bak Rejnmark, Lars |
author_sort | Nielsen, Ole Haagen |
collection | PubMed |
description | Management of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is generally cumbersome for patients and is a massive health-economic burden. In recent years, the immunomodulating effects of vitamin D have gained a huge interest in its possible pathogenic influence on the pathophysiology of IBD. Vitamin D deficiency is frequent among patients with IBD. Several clinical studies have pointed to a critical role for vitamin D in ameliorating disease outcomes. Although causation versus correlation unfortunately remains an overwhelming issue in the illusive chicken versus egg debate regarding vitamin D and IBD, here we summarise the latest knowledge of the immunological effects of vitamin D in IBD and recommend from available evidence that physicians regularly monitor serum 25(OH)D levels in patients with IBD. Moreover, we propose an algorithm for optimising vitamin D status in patients with IBD in clinical practice. Awaiting well-powered controlled clinical trials, we consider vitamin D supplementation to be an affordable and widely accessible therapeutic strategy to ameliorate IBD clinical outcomes. |
format | Online Article Text |
id | pubmed-6788352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-67883522019-10-25 Managing vitamin D deficiency in inflammatory bowel disease Nielsen, Ole Haagen Hansen, Thomas Irgens Gubatan, John Mark Jensen, Kim Bak Rejnmark, Lars Frontline Gastroenterol Small bowel and Nutrition Management of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is generally cumbersome for patients and is a massive health-economic burden. In recent years, the immunomodulating effects of vitamin D have gained a huge interest in its possible pathogenic influence on the pathophysiology of IBD. Vitamin D deficiency is frequent among patients with IBD. Several clinical studies have pointed to a critical role for vitamin D in ameliorating disease outcomes. Although causation versus correlation unfortunately remains an overwhelming issue in the illusive chicken versus egg debate regarding vitamin D and IBD, here we summarise the latest knowledge of the immunological effects of vitamin D in IBD and recommend from available evidence that physicians regularly monitor serum 25(OH)D levels in patients with IBD. Moreover, we propose an algorithm for optimising vitamin D status in patients with IBD in clinical practice. Awaiting well-powered controlled clinical trials, we consider vitamin D supplementation to be an affordable and widely accessible therapeutic strategy to ameliorate IBD clinical outcomes. BMJ Publishing Group 2019-10 2019-01-07 /pmc/articles/PMC6788352/ /pubmed/31656565 http://dx.doi.org/10.1136/flgastro-2018-101055 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Small bowel and Nutrition Nielsen, Ole Haagen Hansen, Thomas Irgens Gubatan, John Mark Jensen, Kim Bak Rejnmark, Lars Managing vitamin D deficiency in inflammatory bowel disease |
title | Managing vitamin D deficiency in inflammatory bowel disease |
title_full | Managing vitamin D deficiency in inflammatory bowel disease |
title_fullStr | Managing vitamin D deficiency in inflammatory bowel disease |
title_full_unstemmed | Managing vitamin D deficiency in inflammatory bowel disease |
title_short | Managing vitamin D deficiency in inflammatory bowel disease |
title_sort | managing vitamin d deficiency in inflammatory bowel disease |
topic | Small bowel and Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788352/ https://www.ncbi.nlm.nih.gov/pubmed/31656565 http://dx.doi.org/10.1136/flgastro-2018-101055 |
work_keys_str_mv | AT nielsenolehaagen managingvitaminddeficiencyininflammatoryboweldisease AT hansenthomasirgens managingvitaminddeficiencyininflammatoryboweldisease AT gubatanjohnmark managingvitaminddeficiencyininflammatoryboweldisease AT jensenkimbak managingvitaminddeficiencyininflammatoryboweldisease AT rejnmarklars managingvitaminddeficiencyininflammatoryboweldisease |